|
Parameters
|
Group A
|
Group B
|
p value
|
|---|
|
N = 52
|
N = 40
|
|---|
|
Variables
|
|
Superficial wound infection
|
2 (3.8 %)
|
1 (2.5 %)
|
0.598
|
|
Deep wound infection
|
0
|
0
|
-
|
|
Pneumonia
|
2 (3.8 %)
|
1 (2.5 %)
|
0.598
|
|
Urinary tract infection
|
2 (3.8 %)
|
1 (2.5 %)
|
0.598
|
|
Venous thrombo-embolism
|
0
|
0
|
-
|
|
Mortality
|
6 (11.5 %)
|
4 (10 %)
|
0.545
|
|
Intra-operative peri-prosthetic fracture
|
0
|
0
|
-
|
|
Post-operative peri-prosthetic fracture
|
0
|
1 (2.5 %)
|
0.435
|
|
Subsidence of the femoral stem
|
18 (34.6 %)
|
6 (15.0 %)
|
0.028*
|
|
Early loosening
|
0
|
0
|
-
|
|
Dislocation
|
0
|
0
|
-
|
|
Overall complications
|
30 (57.7 %)
|
14 (35.0 %)
|
0.020*
|
- Group A: patients without supplementary pharmacologic treatment
- Group B: patients treated with teriparatide
- The values are given as the n (%)
- p-values for between-group comparisons were determined by the chi-squared test and Fisher’s exact test
- *Statistically significant (p < 0.05)
